Daina Graybosch
Stock Analyst at Leerink Partners
(0.80)
# 3,679
Out of 4,784 analysts
119
Total ratings
34.09%
Success rate
-14.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSVT 2seventy bio | Downgrades: Market Perform | $9 → $5 | $4.95 | +1.01% | 6 | Mar 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $89.23 | +33.36% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.29 | +55.04% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.43 | +135.29% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $67.96 | -42.61% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $0.74 | +306.34% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.51 | +2,629.58% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $0.85 | +1,077.44% | 7 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $0.78 | +7,581.47% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $1.98 | +354.55% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $8.17 | +365.12% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.56 | +75.30% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $94.95 | +135.91% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.00 | +1,400.00% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $59 | $6.32 | +833.54% | 7 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.03 | +1,550.49% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.53 | +488.24% | 4 | Feb 25, 2022 |
2seventy bio
Mar 11, 2025
Downgrades: Market Perform
Price Target: $9 → $5
Current: $4.95
Upside: +1.01%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $89.23
Upside: +33.36%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.29
Upside: +55.04%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.43
Upside: +135.29%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $67.96
Upside: -42.61%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $0.74
Upside: +306.34%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.51
Upside: +2,629.58%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $0.85
Upside: +1,077.44%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $0.78
Upside: +7,581.47%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $1.98
Upside: +354.55%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $8.17
Upside: +365.12%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.56
Upside: +75.30%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $94.95
Upside: +135.91%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.00
Upside: +1,400.00%
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $6.32
Upside: +833.54%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.03
Upside: +1,550.49%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.53
Upside: +488.24%